Federal contract award
W81XWH17C0065
IGF::OT::IGF DHA SBIR PH II PROPOSAL NO. A2-6647
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Defense |
| Office | W4PZ USA MED RSCH ACQUIS ACT |
| NAICS | 541711 |
| PSC | AN91 — OTHER MEDICAL - BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | SMALL BUSINESS SET ASIDE - TOTAL |
| Pricing type | COST NO FEE |
| Obligations | $1000.0K |
| Current contract value | $1000.0K |
| Potential contract value / ceiling | $1000.0K |
| Start date | Sep 25, 2017 |
| Current end date | Sep 27, 2022 |
| Potential end date | Sep 27, 2022 |
| Latest award activity | Jan 16, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jan 16, 2025 | P00004 | $-550.0K | ARMY SBIR MEDICAL R&D CONTRACT FOR "PROPOSAL A2-6647 TITLED, "A NOVEL PEPTIDE-BASED TOPICAL THERAPEUTIC TO PROMOTE CORNEAL REGENERATION AND RESTORE CORNEAL BIOMECHANICS FOLLOWING BLAST AND BURN INJURIES" FIRSTSTRING RESEARCH, INC HAS BEEN ACQUIRED BY XEQUEL BIO. INC. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.